Empagliflozin
12 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Empagliflozin for cardiomyopathy, hypertrophic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Empagliflozin for heart defects, congenital | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Empagliflozin for heart failure | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 13 |
| Empagliflozin for heart failure, diastolic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for ketosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for kidney failure, chronic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Empagliflozin for non-alcoholic fatty liver disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for renal insufficiency, chronic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for ventricular dysfunction, right | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |